BTIG raised the firm’s price target on DexCom (DXCM) to $109 from $107 and keeps a Buy rating on the shares after its Q1 results. Revenue topped expectations and a big beat in U.S. sales shows the company is back on track, while its operating expense control offsets gross margin pressures, the analyst tells investors in a research note.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DXCM:
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue